North America Artificial Insemination Market

North America Artificial Insemination Market Size (2023 to 2028)

During the forecast period, the market size for artificial insemination in the North American region is predicted to reach USD 1.15 billion by 2028 from USD 0.76 in 2023, growing at a CAGR of 8.42% from 2023 to 2028.

Infertility refers to the inability of a woman to conceive after having sexual intercourse for one year. In such cases, artificial insemination is one of the treatments developed to help women get pregnant by artificially delivering sperm into the woman's cervix or uterus. The growing number of couples suffering from infertility issues in North American countries is majorly driving the artificial insemination market growth in North America. According to the Centers for Disease Control and Prevention's reproductive health survey, 19% of women between the ages of 15 and 49 cannot conceive in the United States. Furthermore, CDC analyzed that the infertility rate is increasing in the United States; hence, with the escalation in infertility rates, the chances of people opting to get pregnant through artificial insemination also increase, which is expected to contribute to the growth rate of the North American artificial insemination market.

The growing number of Same-sex across North America is expected to accelerate the regional market growth. Intrauterine insemination (a type of artificial insemination) is one of the methods for same-sex couples to have a child. In the case of a lesbian couple, the sperm of the donor is treated and directly deposited into the uterus of one of the lesbians. In the case of a gay couple, the sperm of one of the gay men is delivered into the uterus of the surrogate woman. The access of homosexual couples to avail fertility treatments can elevate the demand for artificial insemination, increasing its market growth rate.

In intrauterine insemination (IUI), the sperm is treated and directly delivered into the woman's uterus; therefore, more than one egg can be fertilized, causing multiple births. According to Statista's U.S. twin birth survey, out of every 1000 births, 31.9 births were twins; therefore, the increase in the birth of more than one child simultaneously can cause severe issues such as miscarriage or preterm birth during pregnancy. This negative impact of IUI can hinder the growth of the artificial insemination market.

This research report on the North American artificial insemination market has been segmented and sub-segmented into the following categories.

By Type:

• Intrauterine
• Intracervical
• Intravaginal
• Intratubal

Based on type, the intrauterine segment is predicted to have a major share of the North American artificial insemination market during the forecast period.

By Source:

• AIH-Husband
• AID-Donor

The AIH segment led the market and is predicted to continue dominating the market in the coming years.

By End-User:

• Hospitals and Clinics
• Fertility Centers
• Others

The fertility centers segment is estimated to hold a major share of the North American market in the coming years.

By Country:

• The United States
• Canada
• Rest of North America

The North American region captured the largest share of the worldwide market in 2022 and is expected to showcase a noteworthy CAGR during the forecast period owing to the rising awareness about artificial insemination technology among the North American population has led women, who have impairment in the fallopian tube, ovaries, or the uterus, to adopt artificial insemination techniques such as intrauterine insemination (treated sperm is released directly into the uterus) or intracervical insemination (sperm is delivered in the cervix of the women). According to the Centers for Disease Control and Prevention, around 33% of Americans have opted for fertility treatments due to their inability to conceive. Hence, the increase in awareness about technological advancement in the medical field has also increased the adoption of those techniques, elevating the growth rate of its market. In addition, according to a community survey conducted by the Census Bureau, there were 1.2 million households of same-sex couples in the United States, and about 60% of them were married in 2021.

The U.S. held a significant share of the North American market in 2021 and is expected to continue dominating the North American market during the forecast period. According to Statista, 14.3% of same-sex couples had children, and intrauterine insemination is the first option same-sex couples consider having a child. Regarding the human rights campaign report on the analysis of the U.S Census Bureau's household pulse survey, there are around 20 million LGBTQIA+ adults in the United States; hence the chances of same-sex couples to opt IUI is higher. Furthermore, according to the analysis of the world population review on CDC's data on the birth rate in the United States, Vermont has the lowest birth rate (8.7 per 1000 population). Hence the demand for artificial insemination treatment might be higher in this region. These factors are anticipated to result in the growth of the artificial insemination market in the U.S.

During the forecast period, the Canadian market is predicted to register a healthy CAGR and is expected to occupy a substantial share of the North American market.              

KEY MARKET PLAYERS:

This report profiles the key participants in the North American artificial insemination market, such as Rocket Medical, INVO Bioscience, Vitrolife, Pride Angel, Genea Limited, MedGyn Products, Inc., Rinovum Women's Health, Conceivex Inc., Tenderneeds Fertility, Hi-Tech Solutions, Fujifilm Irvine Scientific, and Kitazato Corporation.